Neuromod Devices

Executive Summary

Neuromod Devices is an Irish medical technology company founded in 2010 and headquartered in Dublin. The company has developed Lenire, the first and only FDA-approved bimodal neuromodulation device for treating tinnitus. Lenire combines auditory stimulation with electrical tongue stimulation to reduce tinnitus symptoms, offering a non-invasive, drug-free alternative to patients. The device has demonstrated robust clinical efficacy and safety, positioning Neuromod as a leader in the tinnitus space. With a strong focus on scientific innovation, clinical practice enablement, and a patient-centric approach, the company aims to redefine tinnitus care globally. Neuromod is privately held, with its regulatory milestone providing a significant competitive advantage. The global tinnitus market is large and underserved, with limited effective treatments, presenting substantial commercial opportunity. The company continues to invest in clinical evidence, commercialization, and potential expansion into other neurological indications.

Upcoming Catalysts (preview)

• Q4 2026FDA approval for Lenire in pediatric tinnitus or expanded indication60% success
• Q3 2026Positive topline results from European post-market clinical study80% success
• 2026Strategic distribution partnership for Asian market entry70% success